<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
h2
{mso-style-priority:9;
mso-style-link:"Heading 2 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:18.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.Heading2Char
{mso-style-name:"Heading 2 Char";
mso-style-priority:9;
mso-style-link:"Heading 2";
font-family:"Cambria","serif";
color:#4F81BD;
font-weight:bold;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all: <o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>See below for several interesting articles on PCa related topics.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'><br><b>Sent:</b> November 10, 2019 10:15 PM<br><b>To:</b> fyi-prostate-info@googlegroups.com<br><br><o:p></o:p></span></p></div><div><p class=MsoNormal style='line-height:12.0pt'><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'> <o:p></o:p></span></p><p class=MsoNormal style='line-height:12.0pt'><b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>Clinical trial strives for better reoccurring prostate cancer treatment</span></b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><o:p></o:p></span></p><p class=MsoNormal style='line-height:12.0pt'><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><a href="https://www.cbc.ca/news/canada/london/clinical-trial-prostate-london-1.5341201">https://www.cbc.ca/news/canada/london/clinical-trial-prostate-london-1.5341201</a><o:p></o:p></span></p><p class=MsoNormal style='line-height:12.0pt'><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'> <o:p></o:p></span></p><p class=MsoNormal style='line-height:12.0pt'><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'> <o:p></o:p></span></p><p class=MsoNormal style='line-height:12.0pt'><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'> <o:p></o:p></span></p><p class=MsoNormal style='line-height:12.0pt'><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'> <o:p></o:p></span></p><p class=MsoNormal style='line-height:12.0pt'><b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>Transperineal Prostate Biopsy May Be a Safer Alternative</span></b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><o:p></o:p></span></p><p class=MsoNormal style='line-height:12.0pt'><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><a href="https://www.renalandurologynews.com/home/news/urology/prostate-cancer/transperineal-prostate-biopsy-may-be-a-safer-alternative/">https://www.renalandurologynews.com/home/news/urology/prostate-cancer/transperineal-prostate-biopsy-may-be-a-safer-alternative/</a><o:p></o:p></span></p><p class=MsoNormal style='line-height:12.0pt'><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'> <o:p></o:p></span></p><p class=MsoNormal style='line-height:12.0pt'><b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>Oncological and functional outcomes following robot-assisted laparoscopic radical prostatectomy at a single institution: a minimum 5-year follow-up. </span></b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><o:p></o:p></span></p><p class=MsoNormal style='line-height:12.0pt'><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><a href="https://www.urotoday.com/recent-abstracts/endourology-urolithiasis/minimally-invasive-procedures/116282-oncological-and-functional-outcomes-following-robot-assisted-laparoscopic-radical-prostatectomy-at-a-single-institution-a-minimum-5-year-follow-up.html">https://www.urotoday.com/recent-abstracts/endourology-urolithiasis/minimally-invasive-procedures/116282-oncological-and-functional-outcomes-following-robot-assisted-laparoscopic-radical-prostatectomy-at-a-single-institution-a-minimum-5-year-follow-up.html</a><o:p></o:p></span></p></div><p class=MsoNormal>.<o:p></o:p></p></div></body></html>